Skip to main content

Advertisement

SpringerLink
Log in

TLE1 expression in malignant mesothelioma

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Malignant mesothelioma, an aggressive and often lethal tumor commonly associated with asbestos exposure, has been morphologically classified into epithelial, biphasic, and sarcomatoid subtypes. Histological distinction between biphasic or sarcomatoid mesothelioma and synovial sarcoma may be problematic in certain circumstances of intrathoracic location because of their similar clinicopathologic features, including not only their morphology but also occasional positive immunoreaction of mesothelioma markers. TLE1, which plays an important role in Wnt pathway, has been shown to be a specific marker for synovial sarcoma and diagnostically is useful; however, TLE1 expression in malignant mesotheliomas has not been fully evaluated. We immunohistochemically examined the expression of TLE1, factors related to the Wnt pathway including β-catenin and cyclin D1, and mesothelioma markers including calretinin, HBME-1, cytokeratin 5/6, and thrombomodulin in 29 malignant mesotheliomas. TLE1 was variably expressed in 28 malignant mesotheliomas regardless of histomorphological subtype with >25% of positive cells in 20 cases (69.0%). There was no evidence of association of TLE1 expression with immunoreactivity to other markers. Our study showed no or limited value of the immunohistochemical TLE1 expression in distinguishing malignant mesothelioma and synovial sarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Churg A, Roggli V, Galateau-Salle F et al (2004) Mesothelioma. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris C (eds) Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC, Lyon, pp 128–136

    Google Scholar 

  2. Nicholson AG, Goldstraw P, Fisher C (1998) Synovial sarcoma of the pleura and its differentiation from other primary pleural tumours: a clinicopathological and immunohistochemical review of three cases. Histopathology 33:508–513

    Article  CAS  PubMed  Google Scholar 

  3. Okamoto S, Hisaoka M, Daa T, Hatakeyama K, Iwamasa T, Hashimoto H (2004) Primary pulmonary synovial sarcoma: a clinicopathologic, immunohistochemical, and molecular study of 11 cases. Hum Pathol 35:850–856

    Article  PubMed  Google Scholar 

  4. Miettinen M, Limon J, Niezabitowski A, Lasota J (2001) Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol 25:610–617

    Article  CAS  PubMed  Google Scholar 

  5. Daniels DL, Weis WI (2005) β-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 12:364–371

    Article  CAS  PubMed  Google Scholar 

  6. Terry J, Saito T, Subramanian S, Ruttan C, Antonescu CR, Goldblum JR, Downs-Kelly E, Corless CL, Rubin BP, van de Rijn M, Ladanyi M, Nielsen TO (2007) TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 31:240–246

    Article  PubMed  Google Scholar 

  7. Folpe AL, Lloyd RV, Bacchi CE, Rosai J (2009) Spindle epithelial tumor with thymus-like differentiation: a morphologic, immunohistochemical, and molecular genetic study of 11 cases. Am J Surg Pathol 33:1179–1186

    Article  PubMed  Google Scholar 

  8. Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO (2009) Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol 33:1743–1751

    Article  PubMed  Google Scholar 

  9. Kosemehmetoglu K, Vrana JA, Folpe AL (2009) TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol 22:872–878

    Article  CAS  PubMed  Google Scholar 

  10. Tsuji S, Hisaoka M, Morimitsu Y, Hashimoto H, Shimajiri S, Komiya S, Ushijima M, Nakamura T (1998) Detection of SYT-SSX fusion transcripts in synovial sarcoma by reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. Am J Pathol 153:1807–1812

    CAS  PubMed  Google Scholar 

  11. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y, Glatfelter AA, Duray PH, Meltzer PS (2005) Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 65:9226–9235

    Article  CAS  PubMed  Google Scholar 

  12. Beck AH, West RB, van de Rijn M (2010) Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers. Virchows Arch 456:141–151

    Article  CAS  PubMed  Google Scholar 

  13. Ng TL, Gown AM, Barry TS, Cheang MC, Chan AK, Turbin DA, Hsu FD, West RB, Nielsen TO (2005) Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 18:68–74

    Article  CAS  PubMed  Google Scholar 

  14. Pretto D, Barco R, Rivera J, Neel N, Gustavson MD, Eid JE (2006) The synovial sarcoma translocation protein SYT-SSX2 recruits β-catenin to the nucleus and associates with it in an active complex. Oncogene 25:3661–3669

    Article  CAS  PubMed  Google Scholar 

  15. Knösel T, Heretsch S, Altendorf-Hofmann A, Richter P, Katenkamp K, Katenkamp D, Berndt A, Petersen I (2010) TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases. Eur J Cancer 46:1170–1176

    Article  PubMed  Google Scholar 

  16. Lucas DR, Pass HI, Madan SK, Adsay NV, Wali A, Tabaczka P, Lonardo F (2003) Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology 42:270–279

    Article  CAS  PubMed  Google Scholar 

  17. Gotzos V, Vogt P, Celio MR (1996) The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract 192:137–147

    CAS  PubMed  Google Scholar 

  18. Abutaily AS, Collins JE, Roche WR (2003) Cadherins, catenins and APC in pleural malignant mesothelioma. J Pathol 201:355–362

    Article  CAS  PubMed  Google Scholar 

  19. Sakamoto K, Creamer BA, Triplett AA, Wagner KU (2007) The Janus kinase 2 is required for expression and nuclear accumulation of cyclin D1 in proliferating mammary epithelial cells. Mol Endocrinol 21:1877–1892

    Article  CAS  PubMed  Google Scholar 

  20. Stahl M, Ge C, Shi S, Pestell RG, Stanley P (2006) Notch1-induced transformation of RKE-1 cells requires up-regulation of cyclin D1. Cancer Res 66:7562–7570

    Article  CAS  PubMed  Google Scholar 

  21. Horvai AE, Kramer MJ, O’Donnell R (2006) Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med 130:792–798

    CAS  PubMed  Google Scholar 

  22. Ortiz J, Funk C, Schäfer A, Lechner J (2009) Stu1 inversely regulates kinetochore capture and spindle stability. Genes Dev 23:2778–2791

    Article  CAS  PubMed  Google Scholar 

  23. Wang C, Li Z, Fu M, Bouras T, Pestell RG (2004) Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential. Cancer Treat Res 119:217–237

    Article  CAS  PubMed  Google Scholar 

  24. Sekido Y (2008) Molecular biology of malignant mesothelioma. Environ Health Prev Med 13:65–70

    Article  CAS  PubMed  Google Scholar 

  25. Vintman L, Nielsen S, Berner A, Reich R, Davidson B (2005) Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells. Cancer 103:2427–2433

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pathology and Oncology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan

    Atsuji Matsuyama, Masanori Hisaoka, Mahoko Iwasaki, Mao Iwashita, Sachi Hisanaga & Hiroshi Hashimoto

Authors
  1. Atsuji Matsuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masanori Hisaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mahoko Iwasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mao Iwashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sachi Hisanaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Hashimoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matsuyama, A., Hisaoka, M., Iwasaki, M. et al. TLE1 expression in malignant mesothelioma. Virchows Arch 457, 577–583 (2010). https://doi.org/10.1007/s00428-010-0975-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-010-0975-8

Keywords

Search

Navigation